Tags

Type your tag names separated by a space and hit enter

Statin use and risk of Parkinson's disease: A meta-analysis.
Behav Brain Res. 2016 08 01; 309:29-34.BB

Abstract

BACKGROUND AND AIM

Recent studies have suggested that use of statins was associated with risk of Parkinson's disease (PD), however, conclusions were inconsistent.

METHODS

A comprehensive literature search of PubMed, Web of Science, EMBASE and Cochrane Library was performed through March 2015. Studies that evaluated the association between statin use and risk of PD were included in this meta-analysis.Combined relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were also conducted.

RESULTS

A total of 11 studies(2,787,249 patients) were included for meta-analysis(5 case-control and 6 cohort studies). Our results indicated a significant risk reduction of PD(adjusted RR, 0.74, 95% CI 0.62-0.90, P<0.001) for statin users. However, long-term statin use(RR 0.77, 95% CI 0.56-1.07, P=0.12) and baseline low-density lipoprotein cholesterol(LDL-C) level(RR 0.58, 95% CI 0.31-1.07, P=0.08) did not significantly affect the risk of PD. Heterogeneity and publication bias was observed in this meta-analysis (I(2)=74%, P<0.001). Subgroup analysis showed that the difference of the study location can partly affected the pooled estimate(Asian population n=2, adjusted RR, 0.67; 95% CI, 0.56-0.79; Western population n=9, adjusted RR, 0.87; 95% CI, 0.80-0.95).

CONCLUSIONS

Our meta-analysis suggested that statin use is associated with a reduced risk of PD. Statins might be considered as an adjuvant therapy for PD. More randomized clinical trials and observational studies are warranted.

Authors+Show Affiliations

Department of Neurosurgery, Tianjin First Center Hospital, Fukang Road No. 24, Nankai District, Tianjin 300192, China. Electronic address: sjg300192@163.com.Department of Thyroid and Breast Surgery, The Affiliated Hospital of Xuzhou Medical College, Huaihai West Road No. 99, Quanshan, District, Xuzhou City, Jiangsu Province 221000, China. Electronic address: jxb870913@163.com.Department of Internal Medicine,Tianjin United Family Hospital, Tanjiang Road, Hexi District, Tianjin 300221, China. Electronic address: konniedoc@163.com.

Pub Type(s)

Journal Article
Meta-Analysis

Language

eng

PubMed ID

27131781

Citation

Sheng, Zhiguo, et al. "Statin Use and Risk of Parkinson's Disease: a Meta-analysis." Behavioural Brain Research, vol. 309, 2016, pp. 29-34.
Sheng Z, Jia X, Kang M. Statin use and risk of Parkinson's disease: A meta-analysis. Behav Brain Res. 2016;309:29-34.
Sheng, Z., Jia, X., & Kang, M. (2016). Statin use and risk of Parkinson's disease: A meta-analysis. Behavioural Brain Research, 309, 29-34. https://doi.org/10.1016/j.bbr.2016.04.046
Sheng Z, Jia X, Kang M. Statin Use and Risk of Parkinson's Disease: a Meta-analysis. Behav Brain Res. 2016 08 1;309:29-34. PubMed PMID: 27131781.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin use and risk of Parkinson's disease: A meta-analysis. AU - Sheng,Zhiguo, AU - Jia,Xiaobo, AU - Kang,Meini, Y1 - 2016/04/27/ PY - 2016/01/16/received PY - 2016/04/24/revised PY - 2016/04/26/accepted PY - 2016/5/2/entrez PY - 2016/5/2/pubmed PY - 2017/11/29/medline KW - Meta-analysis KW - Parkinson’s disease KW - Statin SP - 29 EP - 34 JF - Behavioural brain research JO - Behav Brain Res VL - 309 N2 - BACKGROUND AND AIM: Recent studies have suggested that use of statins was associated with risk of Parkinson's disease (PD), however, conclusions were inconsistent. METHODS: A comprehensive literature search of PubMed, Web of Science, EMBASE and Cochrane Library was performed through March 2015. Studies that evaluated the association between statin use and risk of PD were included in this meta-analysis.Combined relative risk (RR) estimates and 95% confidence intervals (CIs) were calculated using a random-effects model. Subgroup analyses were also conducted. RESULTS: A total of 11 studies(2,787,249 patients) were included for meta-analysis(5 case-control and 6 cohort studies). Our results indicated a significant risk reduction of PD(adjusted RR, 0.74, 95% CI 0.62-0.90, P<0.001) for statin users. However, long-term statin use(RR 0.77, 95% CI 0.56-1.07, P=0.12) and baseline low-density lipoprotein cholesterol(LDL-C) level(RR 0.58, 95% CI 0.31-1.07, P=0.08) did not significantly affect the risk of PD. Heterogeneity and publication bias was observed in this meta-analysis (I(2)=74%, P<0.001). Subgroup analysis showed that the difference of the study location can partly affected the pooled estimate(Asian population n=2, adjusted RR, 0.67; 95% CI, 0.56-0.79; Western population n=9, adjusted RR, 0.87; 95% CI, 0.80-0.95). CONCLUSIONS: Our meta-analysis suggested that statin use is associated with a reduced risk of PD. Statins might be considered as an adjuvant therapy for PD. More randomized clinical trials and observational studies are warranted. SN - 1872-7549 UR - https://www.unboundmedicine.com/medline/citation/27131781/Statin_use_and_risk_of_Parkinson's_disease:_A_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-4328(16)30261-3 DB - PRIME DP - Unbound Medicine ER -